7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,876.77

+511.14

+0.66%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NSE - Delayed Quote INR

Aurobindo Pharma Limited (AUROPHARMA.NS)

1,681.40 +21.50 (+1.30%)

At close: October 30 at 3:28:19 PM GMT+5:30

Loading Chart for AUROPHARMA.NS

Chart Range Bar

Interval:

In partnership with ChartIQ

What Aurobindo Pharma Shareholders Got Right

What Aurobindo Pharma Shareholders Got Right

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Gets Fair Value Bump As Analysts Weigh Execution

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Gets Fair Value Bump As Analysts Weigh Execution

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions

Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ...

Aurobindo Pharma Ltd (BOM:524804) (Q1 2027) Earnings Call Highlights: Record Revenue Growth and ...

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Fair Value Lift On Stronger Growth Assumptions

Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Fair Value Lift On Stronger Growth Assumptions

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

How The Aurobindo Pharma (NSEI:AUROPHARMA) Story Is Shifting With Fresh Approvals And Valuation Tweaks

How The Aurobindo Pharma (NSEI:AUROPHARMA) Story Is Shifting With Fresh Approvals And Valuation Tweaks

How The Aurobindo Pharma (NSEI:AUROPHARMA) Valuation Story Is Shifting Around Margins And Risk

How The Aurobindo Pharma (NSEI:AUROPHARMA) Valuation Story Is Shifting Around Margins And Risk

Aurobindo Pharma Ltd (BOM:524804) Q3 2026 Earnings Call Highlights: Strong European Growth and ...

Aurobindo Pharma Ltd (BOM:524804) Q3 2026 Earnings Call Highlights: Strong European Growth and ...

Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and ...

Aurobindo Pharma Ltd (BOM:524804) Q2 2026 Earnings Call Highlights: Strong European Growth and ...

Eugia Pharmaceuticals Goes Live with ValGenesis to Modernize CSV

Eugia Pharmaceuticals Goes Live with ValGenesis to Modernize CSV

Mobilize your Website

View Site in Mobile | Classic

Share by: